Poster Session A  
Friday, September 6  
7:45 p.m.-10:00 p.m.

A01 Acidic fibroblast growth factor mediates microenvironmental regulation of MYC in pancreatic cancer. Sohinee Bhattacharyya, Oregon Health and Science University, Portland, OR

A02 SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models. Carine Bossard, Samumed, LLC, San Diego, CA

A03 All the roads bring to Rome: How acetyl-CoA metabolism supports multistep pancreatic carcinogenesis. Alessandro Carrer, Veneto Institute for Molecular Medicine, Padua, Italy

A04 Intratumoral T-cell distribution in murine and patient pancreatic cancer correlates with tissue heterogeneity and survival. Julienne L. Carstens, The University of Texas MD Anderson Cancer Center, Houston, TX

A05 Chromatin dynamics in vivo reveal a complex cell fate transition and master regulators of the development of pancreatic intraepithelial neoplasia. Rohit Chandwani, 1Weill Cornell Medicine, New York, NY

A06 Elucidation of the extracellular adenosine pathway in metastatic pancreatic cancer. Anna M. Chiarella, Columbia University, New York, NY

A07 Mst1r inhibition with LY2801653 increases survival in mice bearing aggressive pancreatic adenocarcinoma organoid model. Betzaira G. Childers, University of Cincinnati, Cincinnati, OH

A08 Human preadipocytes promote pancreatic cancer cellular growth in a diabetes-specific manner. Lawrence Delrosario, University of Michigan, Ann Arbor, MI

A09 CD4 T cells mediated protumorigenic pathway in pancreatic cancer. Prasenjit Dey, The University of Texas MD Anderson Cancer Center, Houston, TX

A10 Using single-cell RNA sequencing to assess the impact of pancreatic oncogenic Kras on macrophage gene expression in vitro. Katelyn Donahue, University of Michigan, Ann Arbor, MI

A11 Combined Src and EGFR inhibition targets STAT3 to induce stromal remodeling and increase drug delivery to improve survival in a mouse model of pancreatic cancer. Austin R. Dosch, University of Miami Miller School of Medicine, Miami, FL

A12 The establishment, maintenance, and maladaptive role of epigenetic memory in mediating pancreatic tumorigenesis. David J. Falvo, Weill Cornell Medicine, New York, NY

A14 Alternative polyadenylation drives oncogenic gene expression in pancreatic cancer. Michael E. Feigin, Roswell Park Comprehensive Cancer Center, Buffalo, NY

A15 Elucidating the role of p53 in the cellular origins of pancreatic cancer development. Brittany M. Flowers, Stanford University School of Medicine, Stanford, CA
Poster Session A  
Friday, September 6  
7:45 p.m.-10:00 p.m.

A16 A novel therapeutic approach to inhibit the bidirectional oncogenic crosstalk between pancreatic cancer cells and the surrounding stroma. Bekesho Geleta, The University of Sydney, Sydney, NSW, Australia

A17 Challenging pancreatic ductal adenocarcinoma and its stroma by a combination of chemo and gene therapy: A preclinical study. Giulia Grisendi, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy

A18 Angiotensin receptor blockers normalize the pancreatic ductal adenocarcinoma stroma by reprogramming carcinoma-associated fibroblasts. William W. Ho, Massachusetts General Hospital, Harvard Medical School, Boston, MA

A19 The role of metaplastic tuft cell chemosensory signaling in pancreatic cancer. Megan T. Hoffman, University of Michigan, Ann Arbor, MI

A20 Gemcitabine primes the pancreatic tumor microenvironment for second-line immunotherapy. Daniel R. Principe, University of Illinois College of Medicine, Medical Scientist Training Program, Chicago, IL

A21 Mass cytometry identifies two distinct fibroblast lineages in pancreatic tumors that differentially regulate antitumor immunity. Colin Hutton, Cancer Research UK Manchester Institute, Manchester, United Kingdom

A22 Molecular subtypes and resistance programs in pancreatic ductal adenocarcinoma elucidated with single-nucleus RNA-seq. William L. Hwang, 1Broad Institute, Cambridge, MA, 2Koch Institute, Cambridge, MA

A24 Gene expression along the glycolysis-cholesterol synthesis axis and outcome in pancreatic cancer. Joanna M. Karasinska, Pancreas Centre BC, Vancouver, BC, Canada

A25 Using biomaterial scaffolds to study the genesis of the immunosuppressive premetastatic niche in pancreatic cancer. Samantha Kemp, University of Michigan, Ann Arbor, MI

A27 Deep learning for analysis of tumor-lymphocyte interactions in pancreatic ductal adenocarcinoma. Soma Kobayashi, Stony Brook University, Stony Brook, NY

A28 Investigation of tumor-cell-intrinsic factors regulating immune infiltration and response to immunotherapy in pancreatic cancer. Jinyang Li, University of Pennsylvania, Philadelphia, PA

A29 Bicompartmental regulation of disease-related gene networks by histone deacetylase inhibition curbs pancreatic cancer progression. Gaoyang Liang, Salk Institute for Biological Studies, La Jolla, CA

A30 Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Matteo Ligorio, Massachusetts General Hospital, Boston, MA
Poster Session A  
Friday, September 6  
7:45 p.m.-10:00 p.m.

A31 Investigating the effect of myeloid Arg1 deletion on tumor growth and CD8+ T-cell infiltration and activation in pancreatic cancer. Rosa E. Menjivar, University of Michigan, Ann Arbor, MI

A32 Adipose-derived mesenchymal stem cell has the differentiation/reprogramming capacity towards two distinct cancer-associated fibroblasts. Yoshihiro Miyazaki, Department of Surgery, University of Tsukuba, Tsukuba, Japan

A33 Single-cell profiling reveals subclonal vulnerabilities to therapy in patient-derived 2D and organoid models. Maria E. Monberg, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

A34 Suppression of dystroglycan function is a hallmark of acinar-to-ductal metaplasia and favors the development of neoplasias and PDAC. John Muschler, Oregon Health and Science University, Portland, OR

A35 Microenvironmental adaptations drive obesity-associated pancreatic cancer. Mandar Deepak Muzumdar, Yale Cancer Biology Institute, Yale University School of Medicine, New Haven, CT

A36 Macrophage metabolism inhibits pancreatic cancer therapy. Christopher J. Halbrook, University of Michigan, Ann Arbor, MI

A37 Mapping super-enhancer signatures in pancreatic ductal adenocarcinoma, cancer-associated fibroblasts and their targeting by epigenetic inhibitors. Pawan Noel, Translational Genomics Research Institute (TGen), Phoenix, AZ

A38 Defining heterogeneity of molecular subtypes in human PDAC with scRNA-Seq. Ki Oh, Stony Brook University, Stony Brook, NY

A39 Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes. Eric O'Neil, University of Oxford, Oxford, United Kingdom

A40 Genomic characterization of locally advanced pancreatic adenocarcinoma. Sarah L. Picardo, Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

A41 Cancer-associated fibroblast (CAF) specific biomarkers in pancreatic ductal adenocarcinoma (PDAC): Transcriptomic and molecular insight. Jayarani F. Putri, Stem Cell Biotechnology Research Group, Industrial Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan

A42 Single-cell RNA-seq analysis of human pancreatic ductal adenocarcinoma identifies a novel cell type expressing the intestinal stem cell marker OLFM4. Manisha Rao, Dept. of Pathology, Stony Brook University Cancer Center, Stony Brook, NY

A43 Spatial organization of pancreatic ductal adenocarcinoma (PDAC)–associated immune cells from the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT) study. David J. Reiss, Celgene Corporation, Seattle, WA
A44 The obesity and pancreatic cancer connection: Crosstalk between adipose, tumor, and stroma. Roopali Roy, Boston Children's Hospital and Harvard Medical School, Boston, MA

A45 Loss of Adar1 in pancreatic acinar cells leads to cell apoptosis and inflammation. Dhwani N. Rupani, The University of Texas MD Anderson Cancer Center, Houston, TX

A46 Senescence induction triggers vascular remodeling and new vulnerabilities to chemo- and immunotherapy in pancreas cancer. Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, New York, NY

A48 Genetic ablation of microRNA-21 profoundly remodels stroma and shortens survival of K-Ras-driven pancreatic cancer mouse models. Lorenzo Sempere, Michigan State University, East Lansing, MI

A49 LIF-mediated crosstalk between pancreatic stellate and cancer cells and its translational application. Yu Shi, Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA

A50 IMPACT inhibits metastatic outgrowth in pancreatic cancer by restraining GCN1-ATF4 signaling. Surajit Sinha, National Cancer Institute, Bethesda, MD

A51 Using single-cell gene expression profiles to determine the cellular landscape of pancreatic ductal adenocarcinoma. Veerin R. Sirihorachai, University of Michigan, Ann Arbor, MI

A52 Modulation of Hedgehog signaling alters immune infiltration in pancreatic cancer. Nina Steele, University of Michigan, Ann Arbor, MI

A53 Meffin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Masahide Takahashi, Nagoya University Graduate School of Medicine, Nagoya, Japan.

A54 Oncogenic Kras modulates pancreas plasticity and the tumor microenvironment. Ashley Velez-Delgado, University of Michigan, Ann Arbor, MI

A55 Pancreatic stellate cells promote pancreatic cancer invasion and metastasis by secretion of soluble factors and through contact-mediated mechanisms. Michael B. Ware, Emory University, Atlanta, GA

A56 A novel deaminase independent function of APOBEC3A catalyzes widespread chromosomal instability to drive an aggressive metastatic phenotype in pancreatic cancer. Sonja Maria Woermann, The University of Texas MD Anderson Cancer Center, Houston, TX

A58 Notch signaling is a key regulator for immune-suppressive function of tumor-associated macrophages in pancreatic adenocarcinoma. Wei Yan, University of Michigan, Ann Arbor, MI

A59 CRISPR screen identifies global regulation of H3K36me2 as an epigenomic mechanism underlying epithelial plasticity in pancreatic ductal adenocarcinoma. Salina Yuan, University of Pennsylvania, Philadelphia, PA
A60 Integrated proteogenomic characterization of pancreatic ductal adenocarcinoma. Liwei Cao, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

A61 Tandem duplicator phenotype: A potentially targetable genomic subgroup in pancreas cancer. Amy X. Zhang, PanCuRx Translational Research Initiative, Ontario Institute of Cancer Research, Toronto, ON, Canada

A62 Regulatory T-cell depletion promotes oncogenic Kras-driven pancreatic carcinogenesis. Yaqing Zhang, University of Michigan, Ann Arbor, MI
**Poster Session B**
Saturday, September 7
12:45 p.m.-3:30 p.m.

**B01** Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma. Christine C. Alewine, National Cancer Institute, NIH, Bethesda, MD

**B02** Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy. Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY

**B03** Targeting tumor-intrinsic metabolic node in pancreatic cancer causes tumor regression, remodels extracellular matrix, and sensitizes to anti-PD1 therapy. Sulagna Banerjee, University of Miami, Miami, FL

**B04** Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer. Adham S. Bear, University of Pennsylvania, Philadelphia, PA

**B05** Paclitaxel protein bound plus gemcitabine plus cisplatin and paricalcitol neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC). Erkut Borazanci, HonorHealth/TGen, Scottsdale/Phoenix, AZ

**B06** The angiotensin receptor blocker and partial PPARγ agonist telmisartan inhibits the growth of pancreatic ductal adenocarcinoma. Yves Boucher, Massachusetts General Hospital, Harvard Medical School, Boston, MA

**B07** Enhancing the effect of autophagy inhibition for pancreatic cancer treatment. Kirsten L. Bryant, University of North Carolina at Chapel Hill, Chapel Hill, NC

**B08** STING and TLR independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody. Katelyn T. Byrne, Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**B09** GSK-3β blockade with 9-ING-41 in pancreas cancer: The 1801 phase 1/2 study. Benedito A. Carneiro, Lifespan Cancer Institute, Brown University, Providence, RI

**B10** Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma. Eileen Carpenter1, Department of Gastroenterology, University of Michigan, Ann Arbor, MI

**B11** circFOXK2 promotes tumor growth and metastasis of pancreatic ductal adenocarcinoma via complexing with YBX1 and hnRNPK. Yangchao Chen, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong

**B13** Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer. Vincent ChungCity of Hope, Duarte, CA
B14 CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX). Fiona Maxwell, Ipsen Bioinnovation, Abingdon, UK


B17 Long noncoding RNA growth arrest specific 5 (GASS) as a proliferation "brake" in aggressive population of CD133+ cells responsible for recurrence in PDAC. Brittany C. Durden, University of Miami, Miami, FL

B18 Defining the role of chromatin remodeling complexes in pancreatic cancer stem cells. Lesley Paige Ferguson, University of California San Diego, La Jolla, CA

B19 Targeting ATM to sensitize pancreatic cancer to immunotherapy and radiotherapy. Michael Green, University of Michigan, Ann Arbor, MI

B20 KrasG12D effector dependencies in the maintenance of pancreatic ductal adenocarcinoma. Adrien Grimont, Weill Cornell Medicine, New York, NY

B21 Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma. Christopher Natale, Linnaeus Therapeutics, Haddonfield, NJ

B22 Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). Pascal Hammel, Hôpital Beaujon, Paris, France

B23 Bioadhesive nanoparticles as a delivery vehicle in pancreatic cancer epithelial cells and pancreatic fibroblasts. Nesrin M. Hasan, Yale University, New Haven, CT

B24 Gastrointestinal microbiome changes in stage IV pancreatic cancer patients treated with pembrolizumab with or without paricalcitol on the Stand Up to Cancer (SU2C) Pancreas Catalyst Trial. Sarah K. Highlander, Translational Genomics Research Institute, Flagstaff, AZ

B25 Engrailed-1 promotes pancreatic cancer progression via antagonizing COMPASS activity. Chang-il Hwang, University of California Davis, Davis, CA

B26 Targeted and sustained drug delivery therapy for localized pancreatic cancer: In vivo validation in porcine models. Laura Indolfi, PanTher Therapeutics, Inc., Cambridge, MA

B27 A phase Ib/II trial of high-dose (HD) ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (MPC). Gayle S. Jameson, HonorHealth Research Institute, Scottsdale, AZ
Poster Session B  
Saturday, September 7  
12:45 p.m.-3:30 p.m.

B28 Novel combination treatment designed to target both metastatic cells and proliferation in pancreatic ductal adenocarcinoma. Michelle Karl, Johns Hopkins University, Baltimore, MD

B29 Outcomes of DNA repair-deficient pancreatic cancers: KU Cancer Center experience. Anup Kasi, University of Kansas, Kansas City, KS

B30 Assessment of CCR5i/maraviroc immunotherapy in combination with PD1 and MR-guided radiotherapy for treatment of pancreatic cancer. Simone Lanfredini, University of Oxford, Oxford, United Kingdom

B31 Type 1 conventional dendritic cells are progressively and systemically dysregulated early in pancreatic carcinogenesis. Jeffrey H. Lin, University of Pennsylvania, Philadelphia, PA

B32 Mutant KRAS downregulates LIFR to enhance glycolysis in pancreatic cancer. Suhu Liu, Montefiore New Rochelle Hospital, New Rochelle, NY

B33 Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) in pancreatic adenocarcinoma. Nune Markosyan, University of Pennsylvania, Philadelphia, PA

B34 The impact of lymphocyte-to-monocyte ratio (LMR) in patients with borderline resectable pancreatic head cancer after curative surgery. Yoji Miyahara, Department of General Surgery, Chiba University, Chiba, Japan

B35 Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Jonathan D. Mizrahi, University of Texas MD Anderson Cancer Center, Houston, TX, 2 University of Arizona Cancer Center, Tucson, AZ

B36 Maintenance chemotherapy after chemoradiation in patients with locally advanced pancreatic cancer. Jonathan D. Mizrahi, University of Texas MD Anderson Cancer Center, Houston, TX

B37 The complex immune-microenvironment heterogeneity in pancreatic cancer. Dana A. Mustafa, Erasmus MC, Rotterdam, The Netherlands

B38 Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma. Robert J. Norgard, University of Pennsylvania, Philadelphia, PA

B40 High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial. Eric O’Neill, Oxford University, Oxford, United Kingdom

B41 Compartment deconvolution in pancreatic cancer with biologic and clinical implications. Xianlu L. Peng, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

B42 Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment. Didier Ritter, Acobiom, Montpellier, France
B43 p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of PTHrP-mediated calcium signaling. Jason R. Pitarresi, University of Pennsylvania, Philadelphia, PA

B44 Clinical utility of semiquantitative evaluation of progesterone receptor immunohistochemistry in neuroendocrine tumors of the pancreas. Sonya Purushothaman, Columbia Presbyterian Hospital, New York, NY

B45 IL35/STAT3 axis as regulator of tolerance and T-cell exclusion in pancreatic cancer. Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

B46 Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734. Nikolina Radulovich, University Health Network, Toronto, ON, Canada

B47 KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL. Cody Rozeveld, Mayo Clinic, Rochester, MN

B48 Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma. Luis I. Ruffolo, University of Rochester Medical Center, Rochester, NY

B49 Precision targeting of M2-like macrophages by the innate defense regulator RP-182 in pancreatic cancer and noncancerous diseases. Rushikesh Sable, National Cancer Institute, Bethesda, MD

B50 Keratin 17 drives tumor aggression and could be targeted for treatment of pancreatic ductal adenocarcinoma. Kenneth R. Shroyer, Department of Pathology, Renaissance School of Medicine, Stony Brook, NY

B51 Examining the differential cellular response of pancreatic cancer cell lines to 12C vs. photon irradiation. Brock J. Sishc, UT Southwestern Medical Center, Dallas, TX

B52 The T-cell architecture of pancreatic ductal adenocarcinoma. Shivan Sivakumar, University of Oxford, Oxford, United Kingdom

B54 The clinical impact and analysis for neoadjuvant chemotherapy against borderline resectable pancreatic cancer: Gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel. Shigetsugu Takano, Chiba University, Chiba, Japan

B56 Endogenous retrovirus transcript levels are associated with immunogenic signatures in multiple metastatic cancer types. James T. Topham, Pancreas Centre BC, Vancouver, BC, Canada

B57 Early-onset pancreatic ductal adenocarcinomas are characterized by a distinct mutational landscape. Erica S. Tsang, BC Cancer, Vancouver, BC, Canada

B58 A phase I/II study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer. Richard Tuli, Memorial Sloan Kettering Cancer Center, New York, NY
B59 IL-6 regulates CTLA4 expression on CD4+ T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma. Michael B. Ware, Emory University, Atlanta, GA

B60 Optimization of biologic scheduling of gemcitabine and abraxane improves treatment response compared to the standard concurrent regimen in preclinical models of pancreatic cancer. Adam R. Wolfe, Ohio State James Cancer Center, Columbus, OH

B61 Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules. Keisuke Yamamoto, Department of Radiation Oncology, New York University School of Medicine, New York, NY

B62 Development of infectivity-selective oncolytic adenovirus for systemic cancer therapy. Masato Yamamoto, University of Minnesota, Minneapolis, MN
C01 Porcupine inhibition redirects mitochondrial metabolism in Wnt-dependent pancreatic cancer. Kristina Y. Aguilera, University of California Los Angeles, Los Angeles, CA

C02 Establishment of a human PDAC explant culture model for treatment prediction and characterization of the tumor microenvironment. Azaz Ahmed, National Center for Tumor Diseases & German Cancer Research Center, Heidelberg, Germany

C03 Evaluation of the implementation of genetic cancer screening guidelines in African American pancreatic cancer patients in a safety net hospital. Taiwo A. Ajose, Morehouse School of Medicine, Atlanta, GA

C04 Treating hepatic metastasis of pancreatic cancer through targeting cancer cell metabolism. Amer Alasadi, Rutgers University, Piscataway, NJ

C05 Comparative quantitative proteomic profiling of neoadjuvantly treated versus treatment-naive human pancreatic ductal adenocarcinoma. Manoj Amrutkar, Department of Pharmacology and Department of Hepato-Pancreato-Biliary Surgery, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

C06 Cholesterol deprivation induces TGFβ signaling to promote basal differentiation in pancreatic cancer. Igor Astsaturov, Fox Chase Cancer Center, Philadelphia, PA

C07 Ciliogenesis and Hh signaling are suppressed downstream of KRas during ADM. Fiona Bangs, University of Oxford, Oxford, United Kingdom

C08 SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates activity against cancer stem cell (CSC)-enriched pancreatic cancer cells and suppresses stemness in vitro. Carine Bossard, Samumed, LLC, San Diego, CA

C09 Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models. Carine Bossard, Samumed, LLC, San Diego, CA

C10 Glutamine deprivation triggers hexosamine salvage in pancreatic cancer cells. Sydney L. Campbell, University of Pennsylvania, Philadelphia, PA

C11 Linoleic acid elevates sirtuin 6 expression and modulates glycolysis and epithelial-mesenchymal transition of pancreatic cancer with loss of Krüpple like factor 10. Hui-Ju Ch'ang, National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan

C12 Lipids signaling contributes to glucose-independent metabolic adaptation in pancreatic ductal adenocarcinoma. Ziheng Chen, The University of Texas MD Anderson Cancer Center, Houston, TX
C13 A “mouse hospital” for preclinical testing of diagnostic and treatment modalities in pancreatic ductal adenocarcinoma (PDA). Cynthia Clendenin, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

C14 A novel RAD51 inhibitor, CYT-0851, shows anticancer activity in preclinical models of pancreatic cancer. Melinda Day, Cyteir Therapeutics, Lexington, MA

C15 A novel model of pancreatic cancer dormancy reveals a dormancy gene signature with human relevance. Crissy Dudgeon, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

C16 The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Dannielle Engle, Salk Institute, La Jolla, CA

C17 Preclinical models to dissect immune escape in pancreatic cancer. William A. Freed-Pastor, Koch Institute at MIT, Cambridge, MA

C18 TGF-beta blockade paradoxically activates non-SMAD signaling. Evan S. Glazer, University of Tennessee Health Science Center, Memphis, TN

C19 Impaired adaptation to negative energy balance in pancreatic cancer-associated wasting. Aaron J. Grossberg, Oregon Health & Science University, Portland, OR

C20 Smpd3 augments chemotherapy and thwarts PDA progression. Audrey M. Hendley, University of California San Francisco, San Francisco, CA

C21 KRAS confers resistance to mechanical compression in pancreatic cancer cells. Liam J. Holt, New York University, New York, NY

C22 Loss of KDM6A promotes pancreatic cancer progression by upregulating epithelial-mesenchymal transition pathway. Sivakumar Jeyarajan, Department of Pathology, University of Michigan, Ann Arbor, MI

C23 Aspiration liquid biopsy (ALB) of pancreatic cancer (PC). Aleksei Kashintsev, National Bioservice, Saint-Petersburg, Russia

C24 Oncogenic mechanism of soluble keratin 17 offers potential therapeutic vulnerability in pancreatic cancer. Ryan R. Kawalerski, Stony Brook Medicine, Stony Brook, NY

C25 Association of mutant KRAS isoforms with weight loss in pancreatic cancer. Haesoo Kim, Cedars-Sinai Medical Center, Los Angeles, CA

C26 KMT2D mediates TGF-β-induced epithelial-to-mesenchymal transition to promote more aggressive pancreatic cancer. Hong S. Kim, University of Michigan, Ann Arbor, MI
C29 Development of a circulating tumor DNA assay in pancreas cancer. Dan King, Stanford University, Palo Alto, CA

C30 Myc amplification is a negative biomarker and a resistance mechanism to trametinib/HCQ treatment, but can be overcome by combined palbociclib/HCQ treatment. Conan Kinsey, Huntsman Cancer Institute, Salt Lake City, UT

C31 The glycosaminoglycan syndecan-4 facilitates pancreatic cancer progression and biologic aggressiveness. Murray Korc, University of California Irvine, Irvine, CA

C32 Therapeutic targeting of keratin 17 and nuclear export uncover therapeutic vulnerabilities of pancreatic cancer. Cindy V. Leiton, Stony Brook University, Stony Brook, NY

C33 Effects of curcumin on pancreatic ductal adenocarcinoma. Adrianna M. Vaskas, Mansfield University, Mansfield, PA

C34 Signaling regulation of epithelial-mesenchymal transition in pancreas cancer cells cultured under hypoxic conditions. Brooke A. McGirr, University of Virginia, Charlottesville, VA

C36 A roadmap for targeting cysteine dependency in a subset of pancreatic cancer. Zeribe C. Nwosu, University of Michigan, Ann Arbor, MI

C37 Setdb1 is required for formation of pancreatic ductal adenocarcinoma by inhibiting apoptosis through regulation of p53 expression. Satoshi Ogawa, Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan

C38 HNF4a regulates progression and molecular subtype of pancreatic ductal adenocarcinoma. Eric L. Snyder, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

C39 A novel rewired pathway of nucleotide metabolism drives chemoresistance in pancreatic cancer. Chun-Hao Pan, Department of Pathology, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, NY

C40 Dissecting key biologic processes in pancreatic cancer metastasis using a genetically defined 3D organoid model. Fong Cheng Pan, Weill Cornell Medicine, New York, NY

C41 Establishment of a novel mouse model of pancreatic squamous carcinoma. Filipa Pinto, Boston University, Boston, MA

C42 Cell culture under perfusion conditions reduces cellular metabolic stress and mimics the in vivo physiologic environment in pancreatic cancer. Daniel Hughes, Department of Oncology, University of Oxford, Oxford, United Kingdom
C43 Assessment of tumor heterogeneity, clonal evolution, and the stromal microenvironment in metastatic pancreatic ductal adenocarcinoma and matched patient-derived organoids. Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, MA

C44 MBD3 stabilizes MYC, leading to metastatic outgrowth of pancreatic cancer in the liver. Alok Ranjan, National Institute of Health, Bethesda, MD

C45 NT219, a novel bispecific inhibitor of STAT3 and IRS1/2, combined with chemotherapy or MEK inhibitor in gemcitabine-resistant pancreatic tumors, induced tumor regression. Hadas Reuveni, TyrNovo Ltd., Tel Aviv, Israel

C46 Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms. Dayana Reverón, Moffitt Cancer Center, Tampa, FL

C47 Plasma ANP and soluble cell adhesion molecule X are novel risk factors for pancreatic cancer-associated thrombosis. Makoto Sano, The University of Tokyo, Tokyo, Japan

C48 Defining mechanisms of adaptation to KRAS G12C inhibitors: Using quantitative proteomics to design combinatorial strategies in pancreatic cancer. Naiara Santana-Codina, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA

C49 Knockdown of FOXN2 enhances adhesion and reduces migration in pancreatic cancer cells. Blanca Santibanez, University of New Hampshire - Manchester, Manchester, NH

C50 Dissecting vulnerabilities of pancreatic tumors’ silent fraction unravels secrets of an alternative cell state. Yogev Sela, University of Pennsylvania, Philadelphia, PA

C51 Targeted inhibition of DUSP1 and DUSP6 suppresses pancreatic adenocarcinoma cells’ growth and glucose metabolism via SAPK/JNK pathway activation. Vanessa S. Silveira, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil

C52 The radioprotector GC4419 enhances the response of PDAC tumors to high dose per fraction radiation exposure. Brock J. Sishc, UT Southwestern Medical Center, Dallas, TX

C53 Liver X receptor ligand targets glutamine metabolism in pancreatic cancer. Shivangi Srivastava, University of Houston, Houston, TX

C54 GATA6 level is a prognostic biomarker for pancreatic cancer in African American patients. Haoyu Tang, Yale University, New Haven, CT

C55 Mapping the pharmacotranscriptomic landscape of pancreatic circulating tumor cell organoids. Fredrik I. Thege, The University of Texas MD Anderson Cancer Center, Houston, TX

C56 Bmi1 is widely expressed in acini and regulates Kras-driven transcription factor networks in early pancreatic neoplasia. Joyce K. Thompson, University of Michigan, Ann Arbor, MI
C57 Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Herve Tiriac, University of California San Diego, La Jolla, CA

C58 p53/p16-independent cytoreduction of chemoresistant pancreatic adenocarcinoma by metabolically optimized epigenetic therapy. Rita Tohme, Cleveland Clinic, Cleveland, OH

C59 NRF2 drives metabolic reprogramming in irradiated pancreatic cancer cells and promotes radioresistance. Erina Vlashi, University of California Los Angeles, Los Angeles, CA

C60 Combination of MEK and autophagy inhibition promotes tumor regression in the KPC mouse model of pancreatic cancer. Urszula N. Wasko, Columbia University, New York, NY

C61 Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer. Shouhui Yang, Laboratory of Human Carcinogenesis, CCR, NCI, Bethesda, MD

C62 The Alliance of Pancreatic Cancer Consortia for Biomarkers for EarlyDetection. Matthew R. Young, National Cancer Institute, Rockville, MD

C63 The analysis of microbiota composition between tumor and normal tissues in pancreatic cancer and the comparison with the public data of NCBI. Eunsung Jun, Asan Medical Center, Seoul, South Korea

C64 C4BPA identified as a novel biomarker is associated with favorable outcome of patients with pancreatic cancer. Kosuke Sasaki, Chiba University, Chiba, Japan

C65 Identifying mechanisms of macrophage-mediated metastasis and therapy resistance in PDAC. Tony J. Wu, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, 2Memorial Sloan Kettering Cancer Center, New York, NY